We represented a developer and manufacturer of surgical devices and implants in a five-year Department of Justice securities fraud investigation concerning allegations that senior executives defrauded investors. The company entered into a deferred prosecution agreement and agreed to pay $30 million to resolve the investigation. Through extensive cooperation and remedial efforts, the company obtained a substantial reduction from the fine that could have been imposed under the U.S. Sentencing Guidelines, and the Department of Justice did not require the appointment of an independent monitor.